Lewiński A, Swietosławski J, Wajs E, Sewerynek E, Karbownik M, Rybicka I, Kułak J, Skowrońska-Jóźwiak E, Małolepsza A
Samodzielna Pracownia Tyreologii, Instytut Endokrynologii AM w Lodzi.
Endokrynol Pol. 1991;42(2):321-51.
2521 patients of the Lódź Outpatient Endocrinological Clinic (2290 females, 231 males; inhabitants of the central region of Poland Lódź City, Lódź Metropolitan Area, Piotrków, Płock, Sieradz, Skierniewice and Włocławek Provinces in which committed dose equivalent to the thyroid was between 2.7-7.0 mSv [min.-max.] in Skierniewice Province and 4.6-11.7 mSv in Płock Province) were included in the study. The patients were divided into 5 groups: I--persons who did not take the protective dose of potassium iodide (KI) after Chernobyl Nuclear Power Plant accident and did not received any treatment with thyroid preparations or hormones at that time (n = 1282), II--patients who receive KI, once or several times (n = 774), III--patients who took orally iodine tincture or other iodine-containing preparations for the above purposes (n-37), IV--patients who took tablets of Thyroideum (Polfa) Thyroideum siccum (dry thyroid extract), once or several times, as a prophylactic action (n = 79), V--patients who were in the course of continuous treatment with Thyreoideum or thyroid hormones at the time of Chernobyl accident (n = 349). The analysis was performed for all the patients jointly, as well as separately for: either sex, three age groups (18-30, 31-55, 56-70 yrs) and 7 administrative areas specified above. All the patients were subjected into complex clinical examination, serum TSH, T3, T4 concentrations, anti-thyroid membrane antibodies (ATMA) and antithyroglobulin antibodies (ATg) titres, as well as ultrasound, scintigraphy, and fine needle aspiration biopsy of the thyroid (the last two according to indications) included. The patients were also examined by means of a special questionnaire (Patient's Inquiry Sheet), which was subsequently submitted to computer analysis. All the doctors' diagnoses from 1986 (17 different diagnoses) and 1990 (27 different diagnoses), as well as the course of diseases, were verified with use of a specially prepared IBM PC/AT computer program ChernStat.(ABSTRACT TRUNCATED AT 400 WORDS)
罗兹门诊内分泌诊所的2521名患者（2290名女性，231名男性；波兰中部地区罗兹市、罗兹都会区、皮奥特克夫、普沃茨克、希隆斯克、斯基尔尼维采和弗沃茨瓦韦克省的居民，其中斯基尔尼维采省甲状腺的受照剂量当量在2.7 - 7.0毫希沃特[最小值 - 最大值]之间，普沃茨克省为4.6 - 11.7毫希沃特）被纳入研究。患者被分为5组：I组——切尔诺贝利核电站事故后未服用碘化钾（KI）防护剂量且当时未接受任何甲状腺制剂或激素治疗的人（n = 1282），II组——接受过一次或多次KI的患者（n = 774），III组——为上述目的口服碘酊或其他含碘制剂的患者（n = 37），IV组——为预防目的服用过一次或多次甲状腺片（Polfa）干甲状腺提取物的患者（n = 79），V组——切尔诺贝利事故发生时正在接受甲状腺片或甲状腺激素持续治疗的患者（n = 349）。对所有患者进行了联合分析，并分别按性别、三个年龄组（18 - 30岁、31 - 55岁、56 - 70岁）以及上述7个行政区进行了分析。所有患者均接受了全面的临床检查，包括血清促甲状腺激素（TSH）、三碘甲状腺原氨酸（T3）、甲状腺素（T4）浓度、抗甲状腺膜抗体（ATMA）和抗甲状腺球蛋白抗体（ATg）滴度，以及甲状腺超声、闪烁扫描和细针穿刺活检（后两项根据指征进行）。还通过一份特殊问卷（患者询问表）对患者进行了检查，随后将问卷提交给计算机分析。1986年（17种不同诊断）和1990年（27种不同诊断）的所有医生诊断以及疾病病程，均使用专门编写的IBM PC/AT计算机程序ChernStat进行了核实。（摘要截取自400字）
